## **Amendments to the Claims**

Claims 1-17 (cancelled)

Claim 18. (original) The compound of Claim 1 wherein the R1, R2, R3 and R4 groups for substitution in formula (I) are selected from the following variables coded R01 thru R16

R variables	R1 group	R2 group	R3 group	R4 group
Combination	choice	choice	choice	choice
Code				
R01	R1	R2	R3	R4
R02	R1	R2	R3	PG1-R4
R03	R1	R2	PG1-R3	R4
R04	R1	R2	PG1-R3	PG1-R4
R05	R1	PG1-R2	R3	R4
R06	R1	PG1-R2	R3	PG1-R4
R07	R1	PG1-R2	PG1-R3	R4
R08	R1	PG1-R2	PG1-R3	PG1-R4
R09	PG1-R1	R2	R3	R4
R10	PG1-01	R2	R3	PG1-R4
R11	PG1-R1	R2	PG1-R3	R4
R12	PG1-R1	R2	PG1-R3	PG1-R4
R13	PG1-R1	PG1-R2	R3	R4
R14	PG1-R1	PG1-R2	R3	PG1-R4
R15	PG1-R1	PG1-R2	PG1-R3	R4
R16	PG1-R1	PG1-R2	PG1-R3	PG1-R4

and;

the Y1, Y2, and Y3 groups for substitution in formula (I) are selected from the following variables coded Y01 thru Y27:

Y variables	Y1 group	Y2 group choice	Y3 group choice
combination	choice		
code			
Y01	Y1	Y2	Y3
Y02	Y1	Y2	PG1-Y3
Y03	Y1	Y2	PG2-Y3
Y04	Y1	PG1-Y2	Y3
Y05	Y1	PG2-Y2	Y3
Y06	Y1	PG1-Y2	PG1-Y3
Y07	Y1	PG1-Y2	PG2-Y3
Y08	Y1	PG2-Y2	PG1-Y3
Y09	Y1	PG2-Y2	PG2-Y3
Y10	PG1-Y1	Y2	Y3
Y11	PG1-Y1	Y2	PG1-Y3
Y12	PG1-Y1	Y2	PG2-Y3
Y13	PG1-Y1	PG1-Y2	Y3
Y14	PG1-Y1	PG1-Y2	PG1-Y3
Y15	PG1-Y1	PG1-Y2	PG2-Y3
Y16	PG1-Y1	PG2-Y2	Y3
Y17	PG1-Y1	PG2-Y2	PG1-Y3
Y18	PG1-Y1	PG2-Y2	PG2-Y3
Y19	PG2-Y1	Y2	Y3
Y20	PG2-Y1	Y2	PG1-Y3
Y21	PG2-Y1	Y2	PG2-Y3
Y22	PG2-Y1	PG1-Y2	Y3
Y23	PG2-Y1	PG1-Y2	PG1-Y3
Y24	PG2-Y1	PG1-Y2	PG2-Y3
Y25	PG2-Y1	PG2-Y2	Y3
Y26	PG2-Y1	PG2-Y2	PG1-Y3
Y27	PG2-Y1	PG2-Y2	PG2-Y3

and;

## Docket No. X-13240A

the X and Z groups and the n variable for substitution in formula (I) are selected from the following variables coded XZn01 thru XZn24:

XZn	X group	Z	n integer
variables	choice	Group	group choice
combination		Choice	
code			
XZn01	X	Z	n
XZn02	X	Z	PG1-n
XZn03	X	Z	PG2-n
XZn04	X	PG1-Z	n
XZn05	X	PG2-Z	n
XZn06	Х	PG3-Z	n
XZn07	X	PG1-Z	PG1-n
XZn08	X	PG2-Z	PG1-n
XZn09	X	PG3-Z	· PG1-n
XZn10	X	PG1-Z	PG2-n
XZn11	X	PG2-Z	PG2-n
XZn12	X	PG3-Z	PG2-n
XZn13	. PG1-X	Z	n
XZn14	PG1-X	Z	PG1-n
XZn15	PG1-X	Z	PG2-n
XZn16	PG1-X	PG1-Z	n
XZn17	PG1-X	PG2-Z	n
XZn18	PG1-X	PG3-Z	n
XZn19	PG2-X	PG1-Z	PG1-n
XZn20	PG2-X	PG2-Z	PG1-n
XZn21	PG2-X	PG3-Z	PG1-n
XZn22	PG2-X	-PG1-Z	PG2-n
XZn23	PG2-X	PG2-Z	PG2-n
XZn24	PG2-X	PG3-Z	PG2-n

Docket No. X-13240A

Claims 19-22 (cancelled)

23. (currently amended) A pharmaceutical composition which comprises a therapeutically effective amount of a compound according to Claim [1 or 2 or 3 or] 18 [or 19 or 20 or 21] and a pharmaceutically acceptable carrier or diluent.

- 24. (currently amended) A method for the treatment or prevention of Inflammatory Diseases, which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound according to Claim [1 or 2 or 3 or] 18 [or 19 or 20 or 21].
- 25. (currently amended) A method for in vivo inhibition of leukotriene B<sub>4</sub> in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound according to Claim [1 or 2 or 3 or] 18 [or 19 or 20 or 21].
- 26. (original) The method of Claim 25 wherein the route of administration is oral and the dose is about 1 to about 1000 milligrams per day.
- 27. (original) The method of Claim 25 wherein the route of administration is parenteral and the dose is about 0.1 to about 100 milligrams per day.

Claims 28-29 (cancelled)